{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:58:29Z","timestamp":1781283509751,"version":"3.54.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Dipeptidyl peptidase-like protein 6 (DPPX) antibody encephalitis is a rare autoimmune encephalitis. Diagnosis and treatment of DPPX remain challenging, particularly in patients with refractory disease. Herein, we report the first case of anti-DPPX encephalitis treated with ofatumumab. The patient had a chronic insidious onset and predominantly presented with severe neuropsychiatric symptoms and the typical triad of symptoms (weight loss, central nervous system hyperexcitability, and cognitive dysfunction). Positive anti-DPPX antibodies in the serum (1:1,000) and cerebrospinal fluid (CSF) (1:100) were detected at the disease peak. The patient was unresponsive to four types of standard immunotherapies (intravenous globulin, plasma exchange, steroids, and tacrolimus), resulting in a treatment switch to ofatumumab. After five doses of injection and 12 months of follow-up, the patient improved well, with only a mild cognitive deficit.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1320608","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T04:47:19Z","timestamp":1719463639000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Case report: Ofatumumab treatment in anti-DPPX autoimmune encephalitis"],"prefix":"10.3389","volume":"15","author":[{"given":"Peicai","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqiong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12883\u2013022-02649\u20137","article-title":"Clinical and imaging analysis to evaluate the response of patients with anti-DPPX encephalitis to immunotherapy","volume":"22","author":"Xiao","year":"2022","journal-title":"BMC Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2174\/1871527319666200708133103","article-title":"Autoimmune encephalitis: current knowledge on subtypes, disease mechanisms and treatment","volume":"19","author":"Nissen","year":"2020","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0896\u20136273(02)01185\u20136","article-title":"The CD26-related dipeptidyl aminopeptidase-like protein DPPX is a critical component of neuronal A-type K+ channels","volume":"37","author":"Nadal","year":"2003","journal-title":"Neuron"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23756","article-title":"Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels","volume":"73","author":"Boronat","year":"2013","journal-title":"Ann Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000991","article-title":"DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients","volume":"83","author":"Tobin","year":"2014","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578214","article-title":"Long term outcomes in patients with anti-DPPX autoimmunity","volume":"384","author":"Dominguez","year":"2023","journal-title":"J Neuroimmunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2149675","DOI":"10.1002\/eji.202149675","article-title":"Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches","volume":"53","author":"Merino-Vico","year":"2023","journal-title":"Eur J Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001088","article-title":"Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the GENERATE registry","volume":"8","author":"Thaler","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.788830","article-title":"Systematic review of safety and efficacy of second- and third-generation CD20-targeting biologics in treating immune-mediated disorders","volume":"12","author":"Kaegi","year":"2021","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14416","article-title":"Ofatumumab for the treatment of refractory anti-LGI1 encephalitis with long-term poor blood glucose control in type 1 diabetes","volume":"29","author":"Chen","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578062","article-title":"The therapeutic effect of ofatumumab in autoimmune encephalitis: A case series","volume":"377","author":"Zhou","year":"2023","journal-title":"J Neuroimmunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000372","article-title":"Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies","volume":"82","author":"Balint","year":"2014","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001053","article-title":"Thymoma and autoimmune encephalitis: clinical manifestations and antibodies","volume":"8","author":"Guasp","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003796","article-title":"DPPX antibody-associated encephalitis: Main syndrome and antibody effects","volume":"88","author":"Hara","year":"2017","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.817896","article-title":"Clinical features and prognosis in Chinese patients with dipeptidyl-peptidase-like protein 6 antibody-associated encephalitis","volume":"12","author":"Miao","year":"2021","journal-title":"Front Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577114","article-title":"Anti-dipeptidyl-peptidase-like protein 6 encephalitis, a rare cause of reversible rapid progressive dementia and insomnia","volume":"339","author":"Zhou","year":"2020","journal-title":"J Neuroimmunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001907","article-title":"Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons","volume":"85","author":"Piepgras","year":"2015","journal-title":"Neurology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1320608\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T04:47:23Z","timestamp":1719463643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1320608\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":17,"alternative-id":["10.3389\/fimmu.2024.1320608"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1320608","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"article-number":"1320608"}}